Loading
Alzheimer Disease / Alzheimer's Disease · Journal article
Experimental Neurology · May 28, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study reports that isoquercetin-ligustrazine co-polymorph (ILCP) attenuates pathological hallmarks of hypoxia-accelerated Alzheimer's disease in ApoE3/4 transgenic mice via suppression of PERK-CHOP endoplasmic reticulum stress signaling. The work establishes a potential mechanistic link between the compound and a stress-response pathway but does not provide efficacy comparison, clinical-stage data, or safety characterization.
Preclinical experimental study in transgenic mice. ApoE3/4 transgenic mice; specific age, sex, number, and health status not stated.. Intervention: Isoquercetin-ligustrazine co-polymorph (ILCP).
Chronic hypoxia exposure for four weeks intensified PERK pathway activity and aggravated AD-associated cognitive deficits in ApoE3/4 transgenic mice. ILCP administration was associated with reduced PERK pathway activation, reduced oxidative stress, alleviated neuronal damage, and preserved synaptic plasticity. PERK-CHOP signaling implicated in hypoxia-driven AD pathology and identified as a potential therapeutic target modulated by ILCP.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings are preclinical proof-of-concept only. They do not establish clinical efficacy, dosing, safety, or tolerability of ILCP in humans and do not yet support clinical trial design or therapeutic recommendation.
Preclinical study in transgenic mice demonstrating mechanism of a novel compound on hypoxia-accelerated AD pathology, without clinical translation or comparative efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
These findings are preclinical proof-of-concept only. They do not establish clinical efficacy, dosing, safety, or tolerability of ILCP in humans and do not yet support clinical trial design or therapeutic recommendation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Alzheimer's disease (AD), a neurodegenerative disorder predominantly affecting the elderly population, is frequently associated with hypoxic conditions, including obstructive sleep apnea and other age-related comorbidities. Arising from various pathological conditions, chronic hypoxia may contribute to the acceleration of AD progression. However, the precise mechanisms underlying hypoxia-induced cellular stress responses, particularly those involving ER stress and the PERK pathway, remain insufficiently explored. In this study, the therapeutic effects of a co-polymorph combining Isoquercetin and Ligustrazine (ILCP) on AD-related pathologies aggravated by chronic hypoxia were investigated. ApoE3/4 transgenic mice were exposed to hypoxic conditions for four weeks; results on oxidative stress levels, β-amyloid (Aβ) deposition, and neuronal apoptosis were assessed. Chronic hypoxia was found to intensify PERK pathway activity, elevate neuronal damage, and further aggravate AD-associated cognitive deficits. ILCP administration was associated with reduced PERK pathway activation, resulting in reduced oxidative stress, alleviated neuronal damage, and preserved synaptic plasticity. These findings support a role for PERK-CHOP signaling in hypoxia-driven AD pathology and suggest a potential link between ILCP treatment and modulation of this pathway.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.